Tempest Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapies in oncology. The company’s research portfolio encompasses both immuno-oncology and precision oncology programs designed to modulate key cancer pathways and enhance anti-tumor immune responses. Lead assets include inhibitors targeting metabolic and signaling pathways that support tumor growth and immune evasion, with multiple candidates advancing through preclinical and early clinical studies.
Founded in 2016 and headquartered in Watertown, Massachusetts, Tempest operates research facilities in the United States and maintains corporate offices in Dublin, Ireland. The dual structure allows the company to leverage U.S.-based scientific talent and Irish incorporation benefits. Tempest collaborates with academic institutions, contract research organizations, and strategic partners to accelerate drug discovery and clinical development, maintaining a pipeline that addresses solid tumors and hematologic malignancies.
Under the leadership of President and Chief Executive Officer Mark McCamish, Tempest has built a management team with extensive experience in oncology drug development and regulatory strategy. The executive team includes seasoned professionals in clinical operations, chemistry manufacturing and controls (CMC), and business development, enabling streamlined advancement of programs from discovery through proof-of-concept trials. The board of directors features industry veterans who guide corporate strategy and governance.
Tempest Therapeutics is committed to translating cutting-edge science into therapies that improve outcomes for cancer patients. By focusing on innovative mechanisms of action and precision patient selection, the company aims to address unmet medical needs and deliver differentiated treatment options. With a growing pipeline and strategic partnerships, Tempest continues to position itself as a dynamic player in the oncology landscape.
AI Generated. May Contain Errors.
